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A study was conducted in a sample of 140 children with sickle cell anemia to 
evaluate the relationship between hematological variables (%HbF, %HbA2, %Hb, 
and mean cell volume) and disease severity. A patient’s severity status was 
determined by whether hetshe was hospitalized, had a transfusion, andlor had a 
pain crisis at 2 evaluation periods; the first was based on a patient’s history taken 
at the initial assessment visit to the Wayne State Comprehensive Sickle Cell 
Center, and the second was based on a 1-3 year follow-up at the center. Fetal 
hemoglobin was a strong predictor of a patient’s hospitalization and transfusion 
status. A decrease in %HbF of 4.76% (one SD of %HbF) was associated with a 
3.58 fold (95% confidence interval, 1.18-7.28) greater odds of being hospiialized 
both prior to initial assessment and on foilow-up, compared to not being hospital- 
ized at either evaluation. Similarly, a decrease in %HbF of 4.76% was associated 
with a 5.56 fold (95% confidence interval, 1.67-18.96) greater odds of having a 
transfusion both prior to initial assessment and on follow-up compared to not 
having a transfusion at either evaluation. Patients who were both hospitalized and 
transfused at initial assessment and on follow-up (n = 12) had a mean %HbF of 
7.59%, while patients who were not hospitalized or transfused at either evaluation 
(n = 19) had a mean %HbF of 13.61%. Fetal hemoglobin was not a significant 
predictor of pain cris,es in this sample of patients. None of the other hematological 
variables were significant predictors of disease severity in this study. The strong 
relationship between %HbF and disease severity identified in this study suggests 
that a single %HbF measurernent may be useful in predicting important aspects of 
the clinical course of children with sickle cell anemia. 
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INTRODUCTION 
The clinical course of sickle cell anemia is highly variable, ranging from 
individuals who experience frequent pain crises, are often hospitalized, and require 
many transfusions to those who rarely, or never experience these events. The Wayne 
State Comprehensive Sickle Cell Center has provided an excellent opportunity to 
evaluate the degree to which the hematological variables predict the frequency of pain 
crises, hospitalizations, and transfüsions. In this study we evaluate the ability of an 
individual’s average leve1 of %HbF, %HbA*, %Hb, and MCV during a 3-year period 
(1977 to 1980) to predict the occurrence of these 3 measures of severity. 
It is well established that the clinical manifestations of sickle cell anemia vary 
with age. Individuals generally do not display clinical symptonis in the first 6 months 
of life; the clinical manifestations often become quite severe in early and middle 
childhood and then may become less severe in adolescence and young adulthood 
warth and Rucknagel, 19831. Alternatively, some patients do not experience signifi- 
cant symptoms until the third decade. Thus, at any given clinical evaluation, a 
patient’s clinical manifestations of the disease will be highly age dependent. In this 
study our strategy was to define clinical severity by combining information collected 
at a patient’s first visit to the Sickle Cell Center with data from routine visits that 
occurred during a 3-year follow-up period. It is expected that combining information 
on severity from these 2 clinical evaluations will provide a more representative 
measure of an individual’s disease severity than if data from only one time period 
were considered. We asked iii this study whether hematologiciil data collected in the 
period between these 2 clinical assessments, at initial assessment and during the 
follow-up period, predíct the observed measures of disease severity . 
METHODS 
Anal ytical 
The proportion of HbF was measured by a radial immunodiffusion assay 
[Chudwin and Rucknagel, 19751. HbF was measured by elution from cellulose acetate 
strips. Total hemoglobin concentration and red cell indices we,re measured using the 
Coulter Model S Counter. 
Sample 
A description of a large sample of patients (n = 360) setm at initial assessment 
at the Wayne State Comprehensive Sickie Cell Center has been presented elsewhere 
[Odenheimer et al, 19831. This sample consisted of children who were first seen at 
the Sickle Cell Center between October 1973 and October 1980; 65 % of the subjects 
had their initial assessment before January 1976. For the shdy reported here we 
selected from this sample 140 individuais who 1) were more than one year old at their 
initial assessment visit; 2) were never part of a special program that may have affected 
their hematological or clinical status (eg , transfusion therap:y) ; 3) reported at the 
initial assessment whether they had ever been hospitalized, transfused, or had a pain 
crisis as a consequence of sickle cell disease; 4) were evaluiited for hematological 
variables at least once in the period Janury 1977 to January 1980; and 5 )  were 
clinically evaluated (number of pain crises, number of hospitalizations, and number 
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of transfusions) for a minimum of 1 year during a follow-up period between January 
1980 and January 1983. The mean age of the 140 individuals studied here was 5.24 
years at their initial assessment and 10.94 years at the midpoint of the 1980 to 1983 
follow-up period. 
Each patient enrolled in the Sickle Cell Center is scheduled for a routine clinical 
evaluation every 3 months. For this report we have only considered the clinical 
assessments between June 1980 and June 1983 as the follow-up period because a more 
comprehensive chica1 evaluation scheme was initiated in 1980. The mean interval 
between a patient’s initial assessment visit to the SicMe Cell Center and the midpoint 
of the follow-up period was 5.7 years. Although each patient was scheduled to be 
seen at the Center every 3 months, this routine varied greatly among patients. In the 
sample of 140 patients considered here, the mean interval between visits was 0.37 
years, the average length of time covered by the clinical assessment during the follow- 
up period was 1.5 years (range, 1-3), and the average number of evaluations per 
individual was 4.1 (range, 1-7). 
Variables Studied and Statistical Analysis 
At each clinic visit, the patient (or the patient’s parents) was asked to report the 
number of hospitalizations, the number of transfusions (transfusions of more than one 
unit of blood were considered as a single transfusion), and the number of pain crises 
of duration greater than 24 hr that occurred since the last routine clinic visit. 
Four severity classes were defined for each of the 3 measures of severity 
(number of pain crises, hospitalizations, and transfusions). The 4 classes were 1) 
those individuals who had at least one event at both evaluations (eg, individuals who 
were hospitalízed both before enrollment to the Center and on at least one occasion 
during the follow-up period); 2) those who had the event recorded at the initial 
assessment as having occurred before enrollment into the study but did not report 
such an event during the follow-up period; 3) those who reported an event during the 
foliow-up but not at the initial assessment; and 4) those who did not report an event 
at either evaluation. 
Because the ranking of the values of an individual’s hematological variables 
remained relatively stable over time [Odenheimer et al, 19841, an individual’s mean 
value for each measurement during the period considered (January 1977 to January 
1980) was taken to represent an individual’s hematological status. Linear regression 
of an individual’s mean value on his average age for the period January 1977 to 
January 1980 was used to correct these data for age variation. 
Each severity measure was coded from O to 2, depending on whether an 
individual had the event at neither the initial assessment nor at the second chica1 
assessment (O), at either initial assessment or at the second clinical evaluation ( l ) ,  or 
at both initial assessment and at the second clinical evaiuation (2). The correlation 
between the 4 severity classes of one measure of severity and the 4 severity classes 
of a second measure was evaluated by the Goodman-Kruskal Gamma test [Goodman 
and Kruskal, 19721, a measure of ordered association. The Goodman-Kruskal Gamma 
varies between - 1 and 1. In general, values close to 1 or - 1 indicate a strong 
monotonic relationship between the variables, and values near zero indicate the lack 
of a monotonic relationship between the variables. 
The association between an individual’s hospitalization, transfusion, and pain 
crisis status at initial assessment and at the clinical assessment of the follow-up period 
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was evaluated using the Kappa statistic [Fleiss, 19811. Kappa is a measure of the 
observed excess concordance between an individual’s status at initial assessment and 
at the second clinical assessment, compared to the concordance expected under a 
hypothesis that these 2 evaluations were independent. Kappa is equal to 1 if the results 
of the 2 evaluations are in perfect agreement, O if the level of agreement is equal to 
that expected under independence, and -Pe/(l-Pe), (where P, is the expected 
agreement under independence) if the results of the 2 evaluations are in total 
disagreement . 
A stepwise logistic risk function analysis was used to model the relationship 
between 6 independent variables (age, sex, %HbF, %HbAZ, %Hb, and MCV) and 
the disease severity measures [Kleinbaum et al, 19821. The logistic risk function is 
given by : 
P(Severity class X) = exp(b, + bixi)/(l + exp(bixi)) 
where b, is the intercept term and bl;  . . . . . b6 are the coefficients relating the 6 
predictor variables, Xi, and the severity outcome. The vector of parameters 
(bi . . . b,) is estimated using the maximum likelihood approach, and hypothesis 
tests are based on the likelihood ratio criterion (X = -2(lnL(complete model) - 
ln(reduced model)). For large samples, X is approximately distributed as a chi square 
with degrees of freedom equal to the differences in the number of parameters in the 
full and reduced model. Odds ratios per change in 1 SD of the predictor variables 
(adjusted for al1 other variables included in the model) were calculated as exp(bix 1 
SD), where bi was the regression coefficient of the ith independent variable being 
evaluated in the logistic model. At the first step of the analysis, the intercept term b, 
was included in the logistic model. At each subsequent step, another variable 
was entered in the model if the significance level of the likelihood ratio test 2 
ln(L(current model)/L(candidate model)), was less than O. 10. If more than one 
variable satisfied this criterion, the combination of variables with the lowest signifi- 
cance level was included in the model, and the selection procedure was repeated. In 
addition, a variable already included in the model was removed if it no longer 
significantly predícted disease (p > 0.15) when an additionai variable was included 
in the model. Prior to carrying out the logistic regression analysis, the average value 
during the period from January 1977 to January 1980 of each of the 4 hematological 
phenotypes considered as independent variables in this analysis was adjusted for the 
average age of patients during the period. 
RES U LTS 
A description of the patients stratified by the severity class assigned for each of 
the 3 severity measures at the initial assessment and for the follow-up period is 
presented in Table 1. Of the 97 patients who had been hospitalized as a consequence 
of sickle cell disease at least once before enrolling in the center, 50 (52%) were also 
hospitalized at Ieast once during the period of follow-up, while of the 37 individuals 
who were not hospitalized before enrolling in the Center, 14 (38%) were hospitalized 
at least once during the 3-year follow-up, 1980 to 1983. The Kappa statistic was not 
significantly different from zero (O. 11 f 0.07), suggesting that there was oniy a weak 
association between the evaluation of an individual’s prior hospitalization status at 
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TABLE 11. Average Levels of Four Age-Adjusted Hematological Variables 
Measured in the Period Between Initial Assessment (IA) and Follow-up Evaluation (FA) for 
Each of the Severitv Classes* 
Severity class 
1A FA N %HbF % HbA2 %Hb Mean cell volume 
Hospitalizations 
Yes Yes 50 8.7 f 3.8 2.8 f 0.4 8.5 k 0.8  90.5 I 13.3 
Yes No 47 8.9 f 4.0 2.9 & 0.4 8.6 & 0.9 86.9 & 10.6 
No Yes 14 9.0 f 5 . 3  2.8 f 0.5 8.6 + 0.9 85.2 f 11.4 
No No 23 13.8 f 5.3  2.7 f 0 . 4  9.0 f 1 . 1  87.4 f 10.9 
Sig level p < 0.001 p = 0.38 p = 0.24 p = 0.34 
Transfusions 
Yes Yes 13 7 . 4 I 3 . 4  2 . 9 k 0 . 5  8 . 0 + 0 . 6  9 5 . 1 I 1 1 . 3  
Yes No 53 9.0 f 4 . 9  2.9 f 0.4 8.5 f 0.9 89.0 f 13.5 
No Yes 9 7.4 f 3.8 2.8 I 0.5 8 .8  f 0.7 88.0 f 8.2 
No No 64 11.0 f 4.4 2.8 I 0.4 8 .8  f 0.9 86.3 $- 10.3 
Sig level p = 0.01 p = 0.58 p = 0.83 p = 0.09 
Pain crises 
Yes Yes 74 9.1 f 3.8  2.8 f 0.4 8.6 f 0.8  89.6 f 12.9 
Yes No 16 8 .8  5 .5  3.0 f 0.4 8.5 ‘fr 1 . 1  86.2 f 9.3 
No Yes 16 11.3 k 4.7 2.7 f 0.4 8.9 f 1.0 85.7 f 8.3 
No No 12 11.4 I 7.2 2.7 f 0.5 8 .3  I 1 . 1  89.0 f 15.2 
Sig leve1 p = 0.17 p = 0.12 p = 0.24 p = 0.57 
*Dcfined by whether a paticnt did or did not cxperience an event that measures degree of severity (a 
hospitalization, a transfusion, or a pain crisis) evaluated in the period prior to initial assessment or in the 
period of follow-up. 
134 
139 
118 
initial assessment and hospitalization status during the 3-year follow-up period. 
Similarly, the association between an individual’s transfusion status at initial assess- 
ment and at the second clinical assessment was also not significantly different from 
zero (Kappa, 0.08 k 0.06). However, there was a stronger association between an 
individual’s pain crisis status at initiai assessment and at the second clinical assessment 
during follow-up (Kappa, 0.25 & 0.10). Of the 90 individuals who had a pain crisis 
before enrolling into the center, 74 (82%) also had a pain crisis at the second clinical 
assessment, while of the 28 individuals who did not have a pain crisis before enrolling 
in the center, 16 (57%) had a pain crisis at the second clinical assessment. 
There were no significant differences among the 4 severity classes of each 
clinical measure for 1) the proportion of males and females, 2) the length of the 
second clinical assessment, and 3 )  the length of time between a patient’s initial 
assessment and the second clinical assessment (data not shown). For the hospitaliza- 
tion measure only, there was a smail (but statisticalíy significant) difference among 
strata for the mean number of clinical visits during the follow-up period. For al1 3 
clinical measures, there were highly significant differences among the strata for the 
average age at initial assessment and average age of the patient for the period of time 
followed in the 3-year follow-up. Those reporting no event at the initial assessment 
were younger in each case. 
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TABLE IlI. Estimates of the Change in the Odds of Experiencing the Event Compared to the 
Odds of Not Experiencing the Event (odds ratio = ORíSD) for Each Unit Change in the SD of the 
F‘redictor Variables, %HbF and Age 
Outcome“ (N) Variable ORlSD 95%CIb 
Hospitalizations 
2 (50) vs O (23) %HbFC 3.58* 1.18-7.28 
&e 1.79 0.43-3.42 
1 (51) vs O (23) % HbF 2.67* 1.53-4.63 
Transhsions 
Age 1 .O6 0.60- 1.88 
2 (13) vs O (64) % HbF 5.56* 1.67-18.96 
Age 3.44* 1.30-9.08 
1 (62) vs O (64) %HbF 1.75* 1.16-2.64 
Age 1.69* 1.13-2.53 
Pain crisis 
2 (74) vs o (12) XHbF 1.67 0.89-3.07 
Age 1.62 0.85-3.08 
1 (32) vs O (12) %HbF 1.21 O.  70-2.13 
Age 1.15 0.58-2.29 
*Significantly different from one at 0.05 leve1 of probability. 
“2 ,  Event both at initial assessment and during the follow-up period; 1,  an event for either of the clinical 
assessments; and O ,  event did not occur. 
bCI, confidence interval on ORISD. 
‘Radial immunodifíüsion assay for HbF. 
The frequencies of the 4 severity classes of the 3 severity measures presented in 
Table 1 did not occur as independent events. There was a highiy significant correlation 
between an individual’s hospitalization classification and transfusion classification 
(Goodman-Kruskai gamma (GK gamma), 0.46 f 0.08) and between an individual’s 
hospitalization classification and pain crisis classification (GK gamma, 0.67 f 0.07). 
The correlation between transfusions and pain was also significantly different from 
zero, but the estimate of association was lower than for the other 2 pairwise compar- 
isons (GK gamma, 0.35 f O. 12). 
The mean values of the age-adjusted hematological variables are presented by 
severity class in Table 11 for each clinical measure. Age-adjusted mean %HbF levels 
were significantly different among the severity classifications of the hospitalization 
and transfusion measures. Scheffe’s contrasts [Neter and Wasserman, 19741 detected 
significantly elevated %HbF levels for individuals in the category that had not been 
hospitalized (n = 23, %HbF 13.58) and in the category that did not report a 
transfusion (n = 64, %HbF 11.0). Mean %HbF levels were not significantly different 
among the other 3 strata for either of these variables, nor were they significantly 
different among the 4 pain crises strata. Mean Hb levels were significantly different 
among severity classes based on transfusion status (p < 0.05) but not for hospitali- 
zations nor for pain crises. Neither %HbA2 nor MCV were significantly different 
among strata for any of the clinical variables considered. 
The results of the stepwise logistic regression analysis used to evaluate the 
magnitude of the associations between 6 independent variables (age, sex, %HbF, 
%HbA2, %Hb, and MCV) and the 4 severity classes of each clinical measure are 
presented in Table 111. For the 3 separate analyses, individuals who were not hospi- 
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TABLE IV. Average %HbF and Age in Years for Individuals Classified According to Whether 
They Reported Hospitalization and a Transfusion (2 yes), Hospitalized or a Transfusion (1 yes), 
or Neither (O yes) at the Initial Assessment (Columns) and During the Follow-up (Rows) 
FOIIOW-UP Variable 
2 Yes %HbF 
N 
Age 
Age 
Age 
1 Yes %HbF 
N 
O Yes %HbF 
N 
Overall %HbF 
N 
Initial assessrnent 
2 Yes 1 Yes O Yes Overall 
7.59 f 3.5" 
12 
14.2 
8.80 & 4.1 
23 
7.87 f 4.5 
25 
13.5 
8.1'7 f 4.2 
60 
13.5 
8.73 f 4.3 
3 
9.5 
9.52 & 3.3 
15 
10.2 
11.11 f 4.3 
24 
11.5 
10.37 f 4.0 
42 
6.49 k 4.6 
4 
9.2 
9.68 f 5.6 
9 
9.2 
13.61 & 4.9 
19 
11.4 
11.61: f 5.6 
32 
7.54 f 3.7 
19 
9.20 k 4.1 
47 
10.62 5.1 
68 
9.68 k 4.7 
134 
"Standard deviation 
TABLE V. Estimates of the Change in the Odds of Experiencing the Combined Hospitaiization 
and Transfusion Events Compared to the Odds of Not Experiencing the Event (odds ratio = OW 
SD) for Each Unit Change in the SD of the Predictor Variables. %HbF and Age 
Outcome" Variable ORISD 95% CIb 
3-4 (33) vs O (19) %HbF 4.67 1.84-1 1.18 
3.07 1.25-7.54 
1-2 (77) vs O (19) %HbF 2.32 1.27-4.04 
Aee 1 .O3 0.57-1.88 
"The number of reports of hospitalization andlor transfusions at initial assessment and during the follow- 
up period, eg, 4 = both hospitalization and transfusion occurred at initial assessment and during the 
follow-up period; and O = neither hospitalization nor transfusion occurred at the initial assessment and 
during the follow-up period. 
bCI, Confidence interval on ORíSD. 
talized, did not have a transfusion, or did not have a pain crisis at both initial 
assessment and at the second clinical assessment were used as the baseline group for 
the comparisons. Of the 6 independent variables considered, only %HbF and age 
were significant predictors of any of these severity measures A decrease in %HbF 
levels of one SD (4.76%) was associated with 3.58 (95% CI = 1.18-7.28) fold 
greater odds of being hospitalized at both evaluations, and 2.67 fold greater odds of 
being hospitalized at one evaluation, compared to the baseline group. Similarly, a 
decrease in %HbF levels of one SD was associated with 5.56 fold greater odds of 
having a transfusion at both evaluations and 1.75 fold greater odds of having a 
transfusion at one evaluation, compared to the baseline group. Age was a significant 
predictor of an individual's transfusion status but not of hospitalization nor of pain 
crises. Neither age nor %HbF were significant predictors of pain crises in this sample. 
In Table IV, we present the mean %HbF values and mean age for severity 
classifications based on hospitalization and transfusions. Nine strata were defined, 
corresponding to the presence or absence of hospitalizations and transfusions at initial 
assessment (both present, one present, or none present) and the presence or absence 
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of these severity measures at the second clinical assessment. Mean %HbF and age 
were both significantly different among the 9 strata (p < 0.001 for %HbF and p < 
0.002 for age). Mean %HbF levels were relatively low for the group that were 
hospitalized and transfused at both initial assessment and at the second clinical 
assessment (4 total events, mean %HbF 7.59) and highest for the group that were not 
hospitalized nor transfused at either evaluation (O total events, mean %HbF 13.61). 
In general, individuals who had the same number of total events (the number of 
events ranged from O to 4) had similar %HbF levels, regardless of whether the events 
occurred prior to initial assessment or at the second clinical assessment. For example, 
mean %HbF levels were very similar in those individuals who had 2 events at initial 
assessment and one event at the second clinical evaluation ( % HbF 8.80), as compared 
to those individuals who had one event at initial assessment and 2 events at the second 
clinical evaluation (%HbF 8.73). However, there was a signifícant difference in mean 
age among those individuals who had their events at initial assessment, as compared 
to those individuals who had their events at the second clinical evaluation. In general, 
individuals who were hospitalized and/or transfused at initial assessment but not at 
the second clinical evaluation were significantly older (13.5 and 11.5 years) than the 
individuals who were hospitalized and/or transfused at the second clinical evaluation 
but not at initial assessment (9.2 years). 
In Table V, we present results of the stepwise logistic regression analysis 
evaluating the magnitude of the association between age and %HbF and the combined 
hospital, transfusion measure. A decrease in %HbF levels of one SD was associated 
with 4.67 fold greater odds of having 3 or 4 events and 2.32 fold greater odds of 
having 1 or 2 events, compared to those having no events. An increasing age was 
also associated with increasing odds of having 3 or 4 events, compared to those 
having no events (odds ratio = 3.07) but not with the odds of having 1 or 2 vs no 
events. 
DISCUSSION 
The most significant result of this study is the demonstration that %HbF is a 
strong predictor of hospitalizations and transfusions in children with sickle cell anemia 
(Tables 111, IV, V). Mean %HbF levels were 6.02% lower for the individuals who 
had at least one hospitalization and one transfusion at both initial assessment and at 
the second clinical assessment (mean %HbF 7.59), as compared to those individuals 
who were not hospitalized nor transfused at either of these evaluations (mean %HbF 
13.61). 
A number of investigators have studied the association between %HbF and 
disease severity, with conflicting results. It has been reported that %HbF is elevated 
in mild sickle cell disease in the Middle East [Ali, 1970; Perrine et al, 1972; 
Haghshenass et al, 19771. Two studies in Jamaica also found an association between 
increased %HbF and reduced severity. Serjeant and Ashcroft [ 19721 found elevated 
levels of %HbF associated with improved skeletal maturation, and Stevens et al 
[1981] found that %HbF levels measured at age 6 months were significantly decreased 
in children manifesting early palpable splenomegaly, dactylitis, and acute splenic 
sequestration or death during the first 2 years of life. However, 2 studies in the United 
States have failed to find these associations between %HbF and disease severity. 
Steinberg et al [ 19731 compared 2 1 patients manifesting mild sickle cell disease (aged 
18-56) with 12 severely affected patients. In their study, a severity score was assigned 
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to each patient based on the occurrence of pain crises, infections, transfusioris, 
neurologic signs, orthopedic defects, leg ulcers, and employment or activity status. 
There was no difference in %HbF levels between the mild and severe groups. Powars 
et al [1980] examined the relationship between 7 clinical iiidicators of morbidity 
(sickle cell crises, acute chest syndrome, hospital admissions, aseptic necrosis, men- 
ingitidsepticemia, and death) and 7 hematological measures (Hb, HCT, absolute 
HbF, %HbF, %HbA2, MCV, and MCHC) collected on 214 patients whose mean age 
was 19.4 years. The only statistically significant finding was an increased Occurrence 
of stroke with lower levels of %HbF. %HbF levels (or any of the other hematological 
variables) were not significantly associated with any of the other severity measures 
considered. 
The results of the different studies are not comparable because there are 
important differences in the age distribution among samples and in the measures of 
severity analyzed. In this population of affected children we have shown a negative 
regression of HbF on age, the proportion of HbF falling from 12% at age 3 to 
approximately 6% at age 20 [Odenheimer et al, 19831. In this istudy the proportion of 
HbF of each individual was corrected by a standard statistical technique to remove 
the effect of varying age. Thus, the difference between the effects of HbF on clinical 
manifestations in this study and those reported by Steinberg er. al [1973] and Powars 
et al [1980] may be due to the different age ranges involved aiid the procedures used 
to adjust for age variability. Similar corrections for age in future studies will facilitate 
comparison with the results of our study. 
The strong relationship between %HbF and disease that we found would not 
have been identified if we had limited our data to those coFlected at either initial 
assessment or at the second clinical assessment. For example, we identified one group 
of individuals who were hospitalized and transfused at initial assessment that did not 
have either of these events at the second clinical assessment. These individuals (Table 
IV) had a mean %HbF level of 7.8% and a mean age of 13.5. Thus, these individuals 
have %HbF levels that are hypothesized to be associated with severe disease, even 
though al1 were disease free at the second clinical assessment. A possible explanation 
for this finding is that these individuals had entered the quiescent period of adoles- 
cence or early adulthood at the second clinical assessment and no longer experienced 
severe complications of the disease. Alternatively, the charige in the number of 
hospitalizations may reflect the influence of care at the Center upon use of hospital 
facilities. We identified a second group of individuals who were not hospitalized nor 
transfused at initial assessment but who did have both of these events at the second 
clinical assessment. These individuals (Table IV) had a mean %HbF level of 6.49% 
and a mean age of 9.2 years. Thus, these patients also had %HbF levels that are 
hypothesized to be associated with severe disease, even though al1 were relatively 
mild at initial assessment. A possible explanation for this finding is that these 
individuals were too young at initial assessment (mean age at initial assessment, 2.7) 
to develop severe complications of the disease. Alternatively, this may be a subset for 
which severity increases after childhood. 
%HbF drops with increasing age, at least until age 35 [Davis, 1976; Rucknagel 
et al, 1979; Pembrey et al, 19781. In our sample, age accounted for approximately 
25% of the variability in %HbF. However, in a previous repon we demonstrated that 
age-adjusted %HbF levels are very stable over time [Odenheimer et al, 19841. The 
correlation between 2 measurements taken an average of 32 rnonths apart was over 
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0.90. The high degree of tracking reported previously and the strong relationship 
between %HbF and severity reported here suggests that a single %HbF measurement 
may be useful in predicting aspects of the clinical course of children with siclúe cell 
anemia, provided it is age corrected and provided the subject is in a steady state and 
the measurement is not during an acute hyperhemolytic episode. The lack of associa- 
tion of pain crises with hospitalization and transfusion in these data was surprising in 
view of the importance of pain in the decision to hospitaiize patients. 
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